Brown Capital Management LLC Incyte Corp Transaction History

Brown Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 08, 2020	SELL	$63.18 - $85.97 $16.5 Million - $22.4 Million	-260,970 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$72.82 - $86.52 $6.77 Million - $8.04 Million	-92,905 Reduced 26.25%	260,970 $19.4 Million
Q2 2019 Aug 13, 2019	SELL	$73.52 - $88.7 $1.21 Million - $1.46 Million	-16,429 Reduced 4.44%	353,875 $30.1 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $602,167 - $835,322	-9,474 Reduced 2.49%	370,304 $31.9 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $12.4 Million - $14.8 Million	-211,373 Reduced 35.76%	379,778 $24.2 Million
Q3 2018 Nov 14, 2018	SELL	$61.75 - $74.23 $48,473 - $58,270	-785 Reduced 0.13%	591,151 $40.8 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $47,523 - $65,588	-781 Reduced 0.13%	591,936 $39.7 Million
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $8.79 Million - $10.7 Million	-105,806 Reduced 15.15%	592,717 $49.4 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $8.93 Million - $11.1 Million	-95,441 Reduced 12.02%	698,523 $66.2 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $86.7 Million - $110 Million	793,964	793,964 $92.7 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Brown Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Brown Capital Management LLC with notifications on news.